These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1017 related articles for article (PubMed ID: 18767981)

  • 21. Phosphoinositide signalling in cancer: beyond PI3K and PTEN.
    Bunney TD; Katan M
    Nat Rev Cancer; 2010 May; 10(5):342-52. PubMed ID: 20414202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic PI3K and its role in cancer.
    Samuels Y; Ericson K
    Curr Opin Oncol; 2006 Jan; 18(1):77-82. PubMed ID: 16357568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The PKB/AKT pathway in cancer.
    Carnero A
    Curr Pharm Des; 2010 Jan; 16(1):34-44. PubMed ID: 20214616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
    Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
    Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
    Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
    PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of T-cell responses by PTEN.
    Buckler JL; Liu X; Turka LA
    Immunol Rev; 2008 Aug; 224():239-48. PubMed ID: 18759931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN at the crossroad of metabolic diseases and cancer in the liver.
    Vinciguerra M; Foti M
    Ann Hepatol; 2008; 7(3):192-9. PubMed ID: 18772845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
    Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets.
    Liu J; Pan Y; Liu Y; Wei W; Hu X; Xin W; Chen N
    J Cell Physiol; 2023 Aug; 238(8):1693-1715. PubMed ID: 37334436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
    Jang K; Kim M; Seo HS; Shin I
    Oncol Rep; 2010 Sep; 24(3):787-93. PubMed ID: 20664988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges in the clinical development of PI3K inhibitors.
    Massacesi C; di Tomaso E; Fretault N; Hirawat S
    Ann N Y Acad Sci; 2013 Mar; 1280(1):19-23. PubMed ID: 23551097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
    Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M
    Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
    Joshi S; Singh AR; Zulcic M; Durden DL
    Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory role of microRNAs on PTEN signaling.
    Ghafouri-Fard S; Abak A; Shoorei H; Mohaqiq M; Majidpoor J; Sayad A; Taheri M
    Biomed Pharmacother; 2021 Jan; 133():110986. PubMed ID: 33166764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis.
    Martelli AM; Cocco L; Capitani S; Miscia S; Papa S; Manzoli FA
    Eur J Histochem; 2007; 51 Suppl 1():125-31. PubMed ID: 17703603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
    Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
    Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN.
    Packer L; Pavey S; Parker A; Stark M; Johansson P; Clarke B; Pollock P; Ringner M; Hayward N
    Carcinogenesis; 2006 Sep; 27(9):1778-86. PubMed ID: 16571650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTEN in liver diseases and cancer.
    Peyrou M; Bourgoin L; Foti M
    World J Gastroenterol; 2010 Oct; 16(37):4627-33. PubMed ID: 20872961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.